← Advanced Medical Solutions overview

Advanced Medical Solutions vs Blue Sail Medical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Advanced Medical Solutions Group plc (AMS.LSE)

Q3 2026
▲1

AMS shareholders back H.B. Fuller's cash takeover; deal on track

  • Shareholders approve H.B. Fuller takeover AMS shareholders voted in favour of H.B. Fuller's recommended cash buyout at meetings on 12 August. That clears a major hurdle, making the deal more likely to complete by year-end and anchoring the share price near the offered terms.

    This is the single biggest new event and the main force now setting AMS's price.

  • Octopus keeps trimming its stake Octopus Investments disclosed its holding fell from 8.66% to 8.28% to 8.07% across July, selling shares each time. The stake is large, but the steady selling suggests it is reducing exposure rather than betting on a higher price.

    Shows a major holder's behaviour, a real counterweight to deal optimism.

  • Broker Investec's routine share dealings Investec, AMS's joint broker, repeatedly bought and sold AMS shares in near-equal amounts around 280p. This is normal market-making tied to its advisory role, not a signal about AMS's health, so it adds little to the bigger picture.

    Explains the other recurring disclosure and why it is not a real driver.

July 2026
▲1

AMS shareholders back H.B. Fuller's cash takeover; deal on track

  • Shareholders approve H.B. Fuller takeover AMS shareholders voted in favour of H.B. Fuller's recommended cash buyout at meetings on 12 August. That clears a major hurdle, making the deal more likely to complete by year-end and anchoring the share price near the offered terms.

    This is the single biggest new event and the main force now setting AMS's price.

  • Octopus keeps trimming its stake Octopus Investments disclosed its holding fell from 8.66% to 8.28% to 8.07% across July, selling shares each time. The stake is large, but the steady selling suggests it is reducing exposure rather than betting on a higher price.

    Shows a major holder's behaviour, a real counterweight to deal optimism.

  • Broker Investec's routine share dealings Investec, AMS's joint broker, repeatedly bought and sold AMS shares in near-equal amounts around 280p. This is normal market-making tied to its advisory role, not a signal about AMS's health, so it adds little to the bigger picture.

    Explains the other recurring disclosure and why it is not a real driver.

Latest
▲1

AMS shareholders back H.B. Fuller's cash takeover; deal on track

  • Shareholders approve H.B. Fuller takeover AMS shareholders voted in favour of H.B. Fuller's recommended cash buyout at meetings on 12 August. That clears a major hurdle, making the deal more likely to complete by year-end and anchoring the share price near the offered terms.

    This is the single biggest new event and the main force now setting AMS's price.

  • Octopus keeps trimming its stake Octopus Investments disclosed its holding fell from 8.66% to 8.28% to 8.07% across July, selling shares each time. The stake is large, but the steady selling suggests it is reducing exposure rather than betting on a higher price.

    Shows a major holder's behaviour, a real counterweight to deal optimism.

  • Broker Investec's routine share dealings Investec, AMS's joint broker, repeatedly bought and sold AMS shares in near-equal amounts around 280p. This is normal market-making tied to its advisory role, not a signal about AMS's health, so it adds little to the bigger picture.

    Explains the other recurring disclosure and why it is not a real driver.

Blue Sail Medical Co Ltd (002382.CS)

Q3 2026
▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

  • First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.

    The profit turnaround is the central new fact that answers why the stock is moving.

  • Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.

    It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.

  • Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.

    The completed divestment is a new capital event that improves cash and focus.

  • Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.

    It is the real counterweight explaining why profit is much lower than divisional results.

August 2026
▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

  • First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.

    The profit turnaround is the central new fact that answers why the stock is moving.

  • Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.

    It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.

  • Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.

    The completed divestment is a new capital event that improves cash and focus.

  • Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.

    It is the real counterweight explaining why profit is much lower than divisional results.

Latest
▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

  • First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.

    The profit turnaround is the central new fact that answers why the stock is moving.

  • Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.

    It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.

  • Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.

    The completed divestment is a new capital event that improves cash and focus.

  • Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.

    It is the real counterweight explaining why profit is much lower than divisional results.